How Retatrutide Works: A Mechanism of Action Explainer

To understand why retatrutide is drawing attention in metabolic research, it helps to understand what the molecule is actually doing at the cellular level. Retatrutide is a triple receptor agonist — it activates three distinct receptor systems simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor (GCGR). Each of these pathways has its own function in the body's metabolic regulation, and the research hypothesis is that engaging all three together produces effects that are greater than the sum of their parts. This article walks through each receptor system and explains what current research suggests about their combined action.

GLP-1 Receptor Agonism: Satiety and Gastric Slowing

GLP-1 is a naturally occurring gut hormone released in response to food intake. When it binds to the GLP-1 receptor — found in the pancreas, brain, gastrointestinal tract, and heart — it triggers a cascade of metabolic effects:

• Appetite suppression: GLP-1 receptor signaling in the hypothalamus and brainstem reduces hunger signals, leading to reduced food intake
• Gastric emptying: The hormone slows how quickly food moves from the stomach into the small intestine, extending the feeling of fullness after meals
• Insulin secretion: GLP-1 stimulates glucose-dependent insulin release from pancreatic beta cells — meaning it promotes insulin secretion when blood glucose is elevated, but not under fasting conditions
• Glucagon suppression: GLP-1 also reduces glucagon secretion from pancreatic alpha cells, contributing to improved postprandial glucose control

GLP-1 receptor agonism is the foundation of the incretin drug class. Semaglutide (a GLP-1 receptor agonist alone) demonstrated significant weight loss in the STEP 1 trial (Wilding et al., 2021), establishing GLP-1 as a meaningful standalone target.

GIP Receptor Agonism: Insulin Sensitization and Adipose Effects

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Historically underappreciated as a therapeutic target, GIP receptor agonism is now understood to add meaningful dimensions to metabolic therapy:

• Insulin sensitization: GIP receptor activation enhances peripheral insulin sensitivity, particularly in adipose tissue and muscle
• Adipose tissue signaling: GIP receptors are expressed on fat cells, and agonism at this receptor may promote lipid utilization and influence how adipose tissue stores and mobilizes energy
• Complementary incretin effect: GLP-1 and GIP appear to act through partially distinct intracellular pathways, which is part of why combining them (as in tirzepatide and retatrutide) may produce additive rather than redundant effects

The role of GIP in synergizing with GLP-1 was a key insight in the development of dual and triple agonists. Coskun et al. (2022) described how the discovery and early development of LY3437943 (retatrutide) was built on understanding the complementary nature of these receptor systems.

Glucagon Receptor Agonism: Energy Expenditure and Hepatic Fat Oxidation

The addition of glucagon receptor agonism is what distinguishes retatrutide from dual agents like tirzepatide. Glucagon is primarily known for raising blood glucose by stimulating the liver to release stored glucose — which is why historically it was viewed as something to suppress, not activate, in metabolic disease. However, glucagon receptor agonism also has a parallel set of effects:

• Hepatic fatty acid oxidation: GCGR activation in the liver stimulates the breakdown of fatty acids for energy, a process that may contribute to fat mass reduction beyond what appetite suppression alone achieves
• Thermogenesis and energy expenditure: Glucagon receptor signaling is associated with increased resting metabolic rate in preclinical models, suggesting it may partially counteract the adaptive metabolic slowdown that often limits long-term weight loss
• Lipolysis: GCGR agonism promotes the mobilization of fat from adipose stores

The key to making glucagon receptor agonism useful in this context — rather than harmful — is the co-presence of GLP-1 receptor agonism, which counterbalances the glucose-raising effect of glucagon. This "check-and-balance" principle was part of the theoretical framework outlined by Finan et al. (2015), whose rodent studies demonstrated that a monomeric triple agonist targeting all three receptors could correct both obesity and diabetes without the hyperglycemic liability expected from glucagon receptor activation alone.

Why Combining All Three May Synergize

The triple agonism hypothesis rests on the idea that these three receptor systems address different nodes in the metabolic network:

• GLP-1 reduces intake (appetite and gastric slowing)
• GIP improves insulin sensitivity and adipose signaling
• GCGR increases output (energy expenditure and fat oxidation)

Targeting only one or two of these nodes leaves the others intact. If the body responds to reduced intake by downregulating energy expenditure (adaptive thermogenesis), GLP-1 alone may hit a ceiling. By simultaneously increasing energy expenditure via GCGR agonism, a triple agent may partially prevent that compensatory slowdown.

This framework is consistent with the dose-response data from the Phase 2 retatrutide trial (Jastreboff et al., 2023), in which the highest doses continued to show incremental weight loss without an apparent plateau — a pattern that has been interpreted as suggesting multiple simultaneous mechanisms sustaining the response.

Key Takeaways

• Retatrutide activates three receptor systems: GLP-1 (satiety, gastric slowing), GIP (insulin sensitization, adipose effects), and GCGR (hepatic fat oxidation, energy expenditure)
• GLP-1 receptor agonism provides the appetite suppression foundation shared across the incretin drug class
• GIP receptor agonism adds insulin sensitization and adipose-level effects that appear to complement rather than duplicate GLP-1 signaling
• Glucagon receptor agonism is hypothesized to increase energy expenditure — its glucose-raising potential is counterbalanced by co-administration of GLP-1 receptor agonism
• Preclinical triple agonist rationale (Finan et al., 2015) and discovery-to-clinic data (Coskun et al., 2022) support the hypothesis that all three pathways acting together produce synergistic metabolic effects